生物制药企业Corcept医疗(纳斯达克代码:CORT)近日披露,其新型内分泌疗法Lobivorli的标准28天疗程批发采购定价为37,900美元。该定价策略为医疗支付方评估这一针对库欣综合征的突破性治疗方案提供了明确的经济参数。公司强调,此价格反映了疗法在临床研究中展现的显著疗效与创新价值。
生物制药企业Corcept医疗(纳斯达克代码:CORT)近日披露,其新型内分泌疗法Lobivorli的标准28天疗程批发采购定价为37,900美元。该定价策略为医疗支付方评估这一针对库欣综合征的突破性治疗方案提供了明确的经济参数。公司强调,此价格反映了疗法在临床研究中展现的显著疗效与创新价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.